MDVIP | AI Transformation Index
MDVIP is structurally well-positioned against AI disruption because the product it sells — licensed physician access and relationship continuity — is legal...

Overview
MDVIP operates a national membership-based primary care network, recruiting and supporting ~1,400 affiliated physicians to run smaller, relationship-intensive practices while charging patients ~$1,800–$2,200/year in direct membership fees for enhanced access and preventive care.
Executive Summary
MDVIP is structurally well-positioned against AI disruption because the product it sells — licensed physician access and relationship continuity — is legally and practically irreplaceable by AI, giving it a durability profile uncommon in healthcare services. The AI opportunity is real but bounded: administrative compression, ambient documentation, and longitudinal member analytics can improve unit economics and physician capacity meaningfully, and there is a credible path to using the 430,000-member dataset to enter employer and payer value-based arrangements. The strategic implication is that MDVIP should invest confidently in AI to improve the administrative envelope around clinical care and expand the between-visit member value proposition, while recognizing that the core moat — physician licensure, trust, and relationship depth — does not require AI defense so much as operational execution.
Durability
How resilient is this business against AI disruption?
Market Substitutability
Profit Pool Migration
Barrier to Entry
Disintermediation Exposure
Switching Costs
Opportunity
How big a deal is AI for this business?
AI Applicability
Improvement Magnitude
Transformation Upside
Domain Intelligence Amplification
66.1
Ciridae AI Score
Durability Rationale
MDVIP's durability is anchored by the irreducible combination of medical licensure requirements, clinical liability, and the patient willingness to pay a premium specifically for a trusted human physician relationship — none of which AI can substitute structurally or legally. The business sits close enough to the clinical delivery layer that it avoids the fate of a pure administrative middleman, and it provides genuine operational value to affiliated physicians that makes bypass unattractive. The primary durability risk is not AI substitution but rather well-capitalized competitors building equivalent physician network infrastructure, or physicians defecting to independent direct primary care models as operational support becomes more commoditized by software.
Opportunity Rationale
AI is a meaningful but not transformative deal for MDVIP — the biggest leverage points are administrative compression (ambient scribing, documentation, prior auth automation) that gives back clinical time to physicians and reduces MDVIP's corporate cost per affiliated physician, and population-level analytics across 430,000 longitudinal members that could improve preventive care quality and open employer/payer market adjacencies. The transformation ceiling is set by the fact that the core product — physician presence, physical examination, and human relationship — is genuinely outside AI's reach, which limits AI applicability breadth even as the opportunity within the reachable surface area is real.
Key Risks
The durability argument assumes the physician-patient relationship remains the irreducible core of what members pay for — but if AI-native health companions (continuous monitoring, ambient diagnosis, agentic care coordination) achieve sufficient clinical trust and regulatory acceptance, the willingness-to-pay for a human physician relationship could erode faster than the regulatory environment suggests today, particularly among younger cohorts less attached to the concierge model.
The opportunity argument assumes MDVIP can capture the AI-enabled administrative and analytics value at the corporate platform level — but if AI tools commoditize physician administrative support (any DPC physician can use ambient scribing independently), the operational differentiation MDVIP provides may compress, reducing physician dependency on the MDVIP platform and weakening both the opportunity and the D4 position simultaneously.
Company Overview
| Headquarters | Boca Raton, Florida |
| Products / Services | Membership-based personalized primary carepreventive and wellness-focused carephysician-affiliate practice transition and succession supportclinical education and quality programsmember services, digital tools and administrative support. |
| Deal Partners |
AI & Tech Initiatives
| Name | Description |
|---|---|
| AI-first payments engineering and agentic development | AI-first engineering workflow for rebuilding MDVIP’s payments integration layer on Azure using Claude Code as the primary development interface, with agentic code generation, automated testing and continuous deployment; the posting describes this as a production engineering practice rather than autocomplete assistance. |
| Applied AI analytics and generative-AI prototyping | Applied-AI analytics program using generative-AI tools, LLMs, AI coding assistants and AI platforms to accelerate analytics, evaluate AI agents, and prototype intelligent document analysis, natural-language analytics interfaces and automated quality assurance. |
PE / Ownership History
| Event | Details |
|---|---|
Goldman Sachs Asset Management and Charlesbank Capital Partners acquire majority ownership October 14, 2021 | The private-equity business of Goldman Sachs Asset Management and funds affiliated with Charlesbank Capital Partners completed the acquisition of MDVIP from Leonard Green and Summit Partners, obtaining majority ownership. Financial terms were not disclosed. Summit and Leonard Green exited their ownership positions according to the announcement. |
Leonard Green & Partners acquires majority ownership from Summit Partners November 15, 2017 | Leonard Green acquired a majority interest from Summit Partners; Summit remained a minority investor. Financial terms were not disclosed. Alyse Wagner was identified in the announcement as Leonard Green’s Partner commenting on the transaction. |
Summit Partners reacquires MDVIP from Procter & Gamble May 2, 2014 | Summit agreed to acquire MDVIP from Procter & Gamble, with closing subject to customary approvals. Terms were not disclosed. Bret Jorgensen returned as executive chairman and later became CEO. |
Procter & Gamble acquires MDVIP from Summit Partners 2009 | Summit sold MDVIP to Procter & Gamble; transaction terms were not identified in the reviewed sources. P&G later pursued divestiture as part of portfolio rationalization. |
Summit Partners makes an initial minority investment in MDVIP 2004 | Summit Partners initially invested in MDVIP and held a minority interest. The investment preceded MDVIP’s sale to Procter & Gamble. |
Executives
| Name | Background |
|---|---|
Larry Kutscher Chief Executive Officer and Chairman | More than 30 years in executive leadership; former CEO of A Place for Mom, CEO of TravelClick, CEO of Register.com, General Manager of Dun & Bradstreet’s Small Business Group, and American Express executive. He became MDVIP CEO in August 2024 and added the chairman role in August 2025. |
Matt Grossman Chief Financial Officer | Joined MDVIP in 2016 as Controller and expanded into company-wide finance and HR leadership. Previously Controller at Charter Schools USA and Audit Manager at a regional public accounting firm; licensed CPA with finance and accounting degrees from Florida Atlantic University. |
Ben Stapleton Chief Operating Officer | Joined in January 2025. Previously COO of Crossroads Treatment Centers, where he led 800 employees and 160 providers across more than 100 centers; previously Chief Clinical Operations Officer at Everside Health and held corporate-development and dialysis-operations leadership roles at DaVita. Earlier experience includes Morgan Stanley, Deutsche Bank and Greywolf Capital. |
John Kane Chief Technology Officer | Technology executive with more than two decades leading engineering, architecture and analytics teams. Former Senior Vice President of Engineering and divisional CTO for Payments at Billtrust, with prior senior roles at TravelClick, Torus Insurance, JetBlue and Towers Perrin Reinsurance. |
Andrea Klemes, DO, FACE Chief Medical Officer | Board-certified internist and endocrinologist. Previously held personal-healthcare, women’s-health and digestive-wellness roles at Procter & Gamble, served as North American Medical Director for bone health, and practiced endocrinology for 10 years in Florida; has led clinical and medical organizations and published clinical research. |
Neal Keltz Chief Product Officer | Joined MDVIP in April 2025. Brings more than 15 years of product, revenue, go-to-market and operations experience, including product initiatives at Togetherwork, TravelClick and American Express. |
Jessica Jacobs Chief Marketing Officer | Joined MDVIP in January 2025; leads the company’s marketing and communications function. Detailed prior-role history was not publicly established in the reviewed sources. |
Theresa Graff Chief Human Resources Officer | Joined MDVIP in January 2025 and leads human-resources strategy and talent organization. Detailed prior-role history was not publicly established in the reviewed sources. |
Ken Nazemetz Executive Vice President, Physician Development | Joined MDVIP in 2008 and has led physician development, including transitions and growth of the affiliated physician network. Detailed prior-role history was not publicly established in the reviewed sources. |
Michele Martello General Counsel | Joined MDVIP in 2008 and oversees legal matters as General Counsel. Detailed prior-role history was not publicly established in the reviewed sources. |
Bret Jorgensen CEO Emeritus and Board Member | Former CEO and chairman who joined MDVIP in 2009. Became CEO Emeritus and board member after the 2024 planned succession; previously co-founded TheraTx and was twice recognized by EY as Healthcare Entrepreneur of the Year. |
Jeffrey Lin, MD, FACC Chief Medical Officer | Appointed in April 2026. Previously National Medical Director and first physician hire at Devoted Health, where he helped build and scale a clinical model serving more than 400,000 members across 29 states; earlier Assistant Professor of Medicine at Mount Sinai Medical Center and cardiology consultant to the NFL Players Association. |